dexmecamylamine (AT-5214)
/ Atacama Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 20, 2024
A Phase 2, Proof-of-concept, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AT-5214 in Subjects with Moderate to Severe Facial Acne Vulgaris
(ANZCTR)
- P2 | N=100 | Recruiting | Sponsor: Atacama Therapeutics Australia, Pty Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2024
Enrollment open • Trial initiation date • Acne Vulgaris • Dermatology
1 to 1
Of
1
Go to page
1